2026 Interim report
Filed with HKEX · Stock code 2575 · · 71 pages · English and Chinese
Xuanzhu Biopharmaceutical Co., Ltd. on 6ix
Earlier from Xuanzhu Biopharmaceutical
- Voluntary announcement first patient enrolled in phase III clinical trial of anaprazole sodium for helicobacter pylori eradication
- List of directors and their role and function
Later from Xuanzhu Biopharmaceutical
- 2025 Annual report - supplemental information
- Voluntary announcement unusual price movements
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2026
- Voluntary announcement phase iii clinical study data of anaprazole sodium for reflux esophagitis presented at ueg week 2026PRESENTED at ueg week 2026
Follow Xuanzhu Biopharmaceutical into a list and get an email when it puts out news.
Follow Xuanzhu Biopharmaceutical